People with lupus have an increased risk of heart disease and stroke due to premature hardening of the arteries. The researchers aimed to evaluate how effectively risk for heart disease was being assessed in a population of lupus patients being cared for in Alberta, Canada.
Establishing agreement on what constitutes a flare of lupus kidney disease could help identify the true status of the kidney in people with lupus.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The researchers hoped to learn whether people with lupus kidney involvement from different races shared the same set of microRNAs.
Current treatments for lupus nephritis in children are toxic and sometimes ineffective. New tests for proteins that might be abnormal in lupus nephritis could help make the diagnosis earlier and might also point to new ways of treating the disease.
Neuropsychiatric lupus (NPSLE) is difficult to diagnose and can be present when disease activity in other organs cannot be identified. The researchers hoped to learn whether antibodies to ganglioside M1 could predict childhood NPSLE any better than standard laboratory measures currently in use.
The researchers hoped to learn whether antibodies to cholesterol regulators are associated with disease activity or heart disease in people with lupus.
The researchers hoped to accurately determine the frequency and outcome of neuropsychiatric lupus, as well as its impacts on quality of life.